Neoantigen Discovery Report Release Part I: Prediction Challenges

Part One of a two part series on the development of Personalis Neoantigen Discovery Report. Part II, Overcoming the Challenges of Neoantigen Prediction will be published in two weeks. The promise of read more...

When an Exome Test Is Part of the Therapy and Not a Diagnostic

Personalis CEO, John West, recently sat down with Mendelspod to discuss personalized cancer vaccines. Listen to the podcast or read the partial transcript below. How are you participating in the receread more...

The state of combination therapies in immuno-oncology

Improved understanding of the cancer-immunity cycle has provided the basis for novel immunotherapeutic approaches. Individual therapeutic agents designed to intervene at different stages of the cycle read more...

The Goldilocks Scenario: Balancing footprint and read depth

Finding the right answers, to the right questions With continued advancements in next generation sequencing (NGS) technologies, the sky’s the limit! As scientists, we now have the ability to interrogread more...

The importance of proper formalin fixation of FFPE specimens

Tumor biopsies are often formalin-fixed and paraffin-embedded (FFPE) for histological staining and archival purposes. Formalin treatment preserves tissue, but also damages nucleic acids and poses a chread more...

Beyond PD-L1: The search for better predictors of beneficial response

The immuno-oncology field as a whole can agree that there is a desperate need for better predictors of not only initial response to immunotherapies, but also of the likelihood of durable response. read more...